Boehringer Ingelheim announces results of phase III data showing that linagliptin significantly lowered blood glucose with an excellent safety and tolerability profile

Please be advised
This release is from Boehringer Ingelheim Corporate Headquarters in Germany. Please be aware that there may be national differences between countries regarding specific medical information, including licensed uses. Please take account of this when referring to the information provided in this document. This press release is not intended for distribution within the U.S.A.

About Diabetes and Type 2 Diabetes
There are approximately 285 million people with diabetes in the adult population worldwide.⁹ The International Diabetes Federation estimates that the number of people with diabetes will increase to 438 million people worldwide by 2030. Nearly four million people within the 20-79 age group are predicted to die from diabetes and its complications in 2010.⁹ Approximately 50% of people with diabetes die of cardiovascular disease,⁹ and more than 8% die of renal causes.¹⁰

For more information about type 2 diabetes, please also visit:

• Media webcast hosted by Boehringer Ingelheim at
  http://www.boehringer-ingelheim-webcast.com/diabetes
• Diabetes Health Lounge website at http://www.DiabetesHealthLounge.com
• DPP-4 mode of action video at http://www.youtube.com/user/diabetesmatters

Boehringer Ingelheim Diabetes Pipeline
Metabolism is one of Boehringer Ingelheim’s core R&D areas and diabetes one of the indications at the centre of interest within the company’s global research network. Boehringer Ingelheim is committed to researching and developing new diabetes compounds with novel modes of action to improve patients’ health and increase overall quality of life. These include:

• The DPP-4 inhibitor linagliptin is the most advanced compound in the Boehringer Ingelheim diabetes portfolio. Linagliptin is being investigated as an oral once-daily tablet for the treatment of type 2 diabetes, as monotherapy and as combination therapy. Linagliptin has a primarily non-renal route of excretion (only approx. 5% excreted via the kidneys).
• The compound BI10773 is a sodium-dependent glucose transporter-2 (SGLT-2) inhibitor. The Phase II clinical trials have concluded. BI10773 blocks renal glucose absorption in the kidneys, thereby improving glycaemic control. The inhibition of SGLT-2 has been seen to have a positive effect on body weight loss and reduction in blood pressure.
• An 11β-HSD1 inhibitor: Inhibition of 11β-HSD1 offers a novel potential therapy for the management of diabetes by lowering intracellular cortisol concentrations resulting in improved insulin sensitivity, blood lipid levels and vascular function. The 11β-HSD1 inhibitor compound currently being studied by Boehringer Ingelheim is in early stage of clinical development.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2009, Boehringer Ingelheim posted net sales of 12.7 billion euro while spending 21% of net sales in its largest business segment Prescription Medicines on research and development.